Soley Therapeutics is a science-first, tech-enabled drug discovery and development company using cells as the world's most powerful sensors to uncover first-in-class medicines. Soley's platform translates the cellular information of stress biology into mechanistic insight, revealing novel drug candidates that otherwise would be missed. Soley deploys full-stack AI via its collaboration with Oracle, including OCI AI Infrastructure, NVIDIA AI Enterprise and NVIDIA Blackwell GPUs. By combining foundational biology, proprietary imaging, first-in-class automation, and integrated AI tools, Soley has rapidly built a pipeline that spans oncology, neurodegenerative disorders, metabolic diseases, and other areas.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/12/26 | $200,000,000 | Series C |
Breyer Capital Doug Leone Family Fund GordonMD Global Investments HRTG Partners RWN Management Surveyor Capital | undisclosed |
